Novavax, Inc. Stock News

Knowing these will help you avoid making suboptimal investing decisions.

Novavax stock took a hit in mid-October after the FDA placed its request to begin testing two new products on hold. Is NVAX stock a sell?

Let's look beyond this piece of bad news from regulators.

Novavax stock fell 20% in one trading session on the news.

Novavax, Inc. (NASDAQ:NVAX) shares plummeted on Wednesday on news it faced a clinical hold on its CIC flu combination vaccine program after a serious adverse event (SAE) was reported in a Phase 2 trial participant. The SAE, motor neuropathy, surfaced in September 2024, nearly two years after the individual received the vaccine in January 2023.

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.

Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped research on the biotech firm's experimental combination COVID-19 and flu vaccine and standalone flu shot following a report of nerve damage in one patient who took the combination injection.

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending shares of the company down sharply.  The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial that finished in July last year.